Financial News

My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

571.88 -0.72 (-0.12%)
Streaming Delayed Price Updated: 10:01 AM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 81,201
Open 573.43
Bid (Size) 570.50 (2)
Ask (Size) 573.25 (1)
Prev. Close 572.59
Today's Range 567.30 - 577.00
52wk Range 476.49 - 1,165.85
Shares Outstanding 91,779,465
Dividend Yield 0.31%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
U.S. Economy Braces for Significant Slowdown: Leading Indicators Signal Weakening, Not Yet Recession
The U.S. economy finds itself at a critical juncture, as signals from The Conference Board's Leading Economic Index (LEI) point toward a sustained period of economic weakening. While the LEI's... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire

Performance

YTD
-20.0%
-20.0%
1 Month
-0.4%
-0.4%
3 Month
+9.4%
+9.4%
6 Month
-15.7%
-15.7%
1 Year
-50.4%
-50.4%

More News

Read More
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials
Via Stocktwits
Regeneron Stock Rallies After Therapy For Autoimmune Disease Meets Late-Stage Trial Goals: Retail Thinks Stock Might Hit An All-Time Low Soon
Via Stocktwits
Tariffs Cast a Long Shadow: Consumer Prices Soar Across Essential Goods
Via MarketMinute
Topics Economy Government World Trade
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy
Via Benzinga
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Cash-Producing Stocks That Concern Us
Via StockStory
Global Economic Slowdown and Escalating Tariffs: A Looming Threat to Market Growth
Via MarketMinute
Topics Economy Supply Chain World Trade
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Via Benzinga
Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
2 Beaten-Down Stocks to Buy on the Dip
Via The Motley Fool
Topics Government World Trade
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors
Via Benzinga
Sanofi Tumbles As New Eczema Drug Lags Dupixent's 'Compelling Bar'
Via Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
Via StockStory
Topics Artificial Intelligence
Cisco, ServiceNow, Truist Financial And A Health Care Stock On CNBC's 'Final Trades'
Via Benzinga
REGENERON PHARMACEUTICALS (NASDAQ:REGN): A Prime Value Investing Candidate with Strong Fundamentals
Via Chartmill
MongoDB To Rally Around 63%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Where Regeneron Pharmaceuticals Stands With Analysts
Via Benzinga
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Via Benzinga
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Top S&P500 movers in Monday's session
Via Chartmill
FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles
Via Benzinga
2 Biotech Stocks That Could Soar 21% and 245% According to Wall Street's Top Analysts
Via The Motley Fool

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 571.88
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 09/16/25 10:01 AM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 52.49B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 52B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback